Biocept, which develops and markets cancer diagnostic tests, raised $19 million by offering 1.9 million shares at $10, the low end of the range of $10 to $12. The company had originally filed to offer 1.8 million shares. At the IPO price, the company commands a market cap of $48 million, which is below our market cap requirement of $50 million. As such, the deal has been excluded from our IPO stats. Biocept plans to list on the NASDAQ under the symbol BIOC. Aegis Capital acted as the lead manager on the deal.
